Baidu
map

Nat Genet:识别癌症驱动因子的新方法

2014-08-28 佚名 生物谷

近日,一组研究人员开发出一种能查明癌症的基因“驱动程序”的新综合方法,新研究揭示了可能是治疗乳腺癌的八个可行靶标基因。 这项研究发表在Nature Genetics杂志上。研究人员研究了多种致癌途径,涉及正常细胞转变成癌细胞过程中的基因变异,其中包括控制癌细胞生长率的基因途径。细胞的高生长速率也被称为细胞增殖,被认为与乳癌患者不良预后有关。 分析多种类型基因组数据,研究人员能够确定在基因组

近日,一组研究人员开发出一种能查明癌症的基因“驱动程序”的新综合方法,新研究揭示了可能是治疗乳腺癌的八个可行靶标基因。

这项研究发表在Nature Genetics杂志上。研究人员研究了多种致癌途径,涉及正常细胞转变成癌细胞过程中的基因变异,其中包括控制癌细胞生长率的基因途径。细胞的高生长速率也被称为细胞增殖,被认为与乳癌患者不良预后有关。

分析多种类型基因组数据,研究人员能够确定在基因组DNA水平扩增的8个基因,这8个基因对于管腔乳腺癌细胞增殖所必需的。

使用这种新的计算方法,我们能够利用现有丰富数据资源,确定针对乳腺癌患者特定子集的若干新的潜在药物靶标。

事实上,所鉴定出的8个基因中的基因CPT1A已经是淋巴瘤药物治疗靶标,并很有可能被用于乳腺癌患者治疗。靶向CPT1A药物在体外、淋巴瘤的小鼠模型中已被证明能抑制人类肿瘤细胞系生长。

利用多种数据类型的全面和综合分析,包括基因表达数据,体细胞突变,DNA拷贝数以及功能基因组学数据集,能更好地了解癌症的驱动基因。

关注MedSci官方微信,即可获得10个积分

搜索公众号:medsci  

原始出处

Gatza ML1, Silva GO2, Parker JS1, Fan C3, Perou CM4.An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.Nat Genet. 2014 Aug 24

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880259, encodeId=dadc1880259ef, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 15 18:18:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685965, encodeId=6e27168596546, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Apr 03 10:18:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733711, encodeId=41f41e33711dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Dec 22 08:18:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903069, encodeId=371b19030696b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Dec 21 14:18:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048615, encodeId=d7ff2048615b7, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Oct 02 19:18:00 CST 2014, time=2014-10-02, status=1, ipAttribution=)]
    2014-10-15 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880259, encodeId=dadc1880259ef, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 15 18:18:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685965, encodeId=6e27168596546, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Apr 03 10:18:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733711, encodeId=41f41e33711dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Dec 22 08:18:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903069, encodeId=371b19030696b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Dec 21 14:18:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048615, encodeId=d7ff2048615b7, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Oct 02 19:18:00 CST 2014, time=2014-10-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880259, encodeId=dadc1880259ef, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 15 18:18:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685965, encodeId=6e27168596546, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Apr 03 10:18:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733711, encodeId=41f41e33711dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Dec 22 08:18:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903069, encodeId=371b19030696b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Dec 21 14:18:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048615, encodeId=d7ff2048615b7, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Oct 02 19:18:00 CST 2014, time=2014-10-02, status=1, ipAttribution=)]
    2014-12-22 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880259, encodeId=dadc1880259ef, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 15 18:18:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685965, encodeId=6e27168596546, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Apr 03 10:18:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733711, encodeId=41f41e33711dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Dec 22 08:18:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903069, encodeId=371b19030696b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Dec 21 14:18:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048615, encodeId=d7ff2048615b7, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Oct 02 19:18:00 CST 2014, time=2014-10-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1880259, encodeId=dadc1880259ef, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 15 18:18:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685965, encodeId=6e27168596546, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Apr 03 10:18:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733711, encodeId=41f41e33711dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Dec 22 08:18:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903069, encodeId=371b19030696b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Dec 21 14:18:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048615, encodeId=d7ff2048615b7, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Oct 02 19:18:00 CST 2014, time=2014-10-02, status=1, ipAttribution=)]
    2014-10-02 cy0324

相关资讯

魅惑般的毁灭——癌症时装秀

加拿大的不列颠哥伦比亚大学(University of British Columbia)曾进行了一项名为“癌症时装:毁灭与美丽相关性”的跨学科研究,旨在引导更多的人关注女性癌症患者。这10套礼服是该校戏剧与电影学院助理教授 Jacqueline Firkins 受癌细胞的显微图像启发而创作的。 1. 脑浸润 “我们关于癌症的看法,以及我们加诸癌症之上的那些隐喻,不过反映了我们

Immunity:揭示肠道“守卫”细胞的发育机制

近日,来自洛克菲勒大学等处的研究人员通过研究揭示了机体上皮内淋巴细胞(IELs)的新型发育机制,相关研究刊登于国际杂志Immunity上,该研究或为开发治疗肠道炎性疾病,比如炎性肠病、乳糜泻甚至是癌症的新型疗法提供了一定的研究思路。 研究者Daniel Mucida教授说道,上皮内淋巴细胞起源于胸腺组织,或许其可以由成熟淋巴细胞所诱导产生,通过研究我们揭示了自然上皮内淋巴细胞及诱导的上皮内

Cell:癌症分类步入“大革命时代”?

近期,Cell在线发表了一篇文章,公布了癌症基因图谱(TCGA)部分的研究结果。 这是迄今为止最大型研究,利用多平台方法,观察了来自12种不同癌症类型的3500个肿瘤样本的分子和遗传学特征。这是很重要的,之前的分子研究大多数侧重于1种技术,在病理上将肿瘤类型定义为“组织/器官”病变类型。 这种新的方法借助6种不同的平台研究综合的基因组学——大多数是诸如DNA和RNA测序,联合蛋白质表达图谱

JCB:发现可加速癌症及神经性障碍疾病治疗的细胞“导航系统”

近日,刊登在国际杂志Journal of Cell Biology上的一篇研究论文中,来自杜克大学的研究人员通过研究发现,细胞表面的一种“巡回检测系统”或许会为开发治疗诸多疾病,比如癌症、帕金森疾病、肌萎缩侧索硬化(ALS)的新型疗法带来帮助。 文章中,研究人员以线虫作为模式动物进行研究,线虫的细胞可以突破正常组织的边界进入到其他组织和器官中,这种反应对于其进行许多正常的发育过程十分重要,对

STM:注射细菌可治癌症?靠谱吗?

一些古老的医学技术可能有时候听上去比较疯狂,但也许隐藏者秘密,比如中医的刮痧和针灸,西方的热疗和放血疗法,这些方法或者都值得利用新的技术继续研究和探索。直接注射有毒细菌作为治疗肿瘤的方法,看上去就不是那么靠谱,但最新用狗和人做的一项研究发现,直接将细菌注射到肿瘤体内能有效控制肿瘤生长,甚至能完全消除肿瘤。这一细菌疗法容易让人们联想起一战期间用疟疾治疗梅毒的研究,都属于以毒攻毒的概念。 细菌感染

Mol Carcinogen:达沙替尼有望用于治疗乳腺癌和其他癌症

据Loyola大学芝加哥Stritch医学院研究人员证实:白血病药物—达沙替尼,很有希望用于治疗皮肤癌,乳腺癌和其他一些癌症。 达沙替尼属多酪氨酸激酶抑制剂,用于治疗白血病。但用达沙替尼其他类型肿瘤细胞时,研究人员发现该药物能使肿瘤细胞聚集在一起,从而防止它们迁移。没有迁移能力,癌细胞不能转移。 Mitchell Denning博士和他的同事发现了达沙替尼抑制肿瘤细胞间黏附的背后分子

Baidu
map
Baidu
map
Baidu
map